EVALUATION OF PROTEINURIA IN ?-THALASSEMIA MAJOR PATIENTS WITH AND WITHOUT DIABETES MELLITUS TAKING DEFERASIROX
(Abstract release date: 05/19/16)
EHA Library. Karimi M. 06/09/16; 135120; PB2220
Prof. Mehran Karimi
Contributions
Contributions
Abstract
Abstract: PB2220
Type: Publication Only
Background
Beta-Thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the Deferasirox is proteinuria.
Aims
This study aimed to investigate the safety of deferasirox on kidney function in diabetic and non-diabetic Beta-Thalassemia Major patients.
Methods
In this cross-sectional study, 70 patients who take deferasirox (Exjade-Novartis) 20-40mg/kg/day were studied. Exclusion criteria included patient with renal failure, proteinuria, hepatitis B, hepatitis C and the patients who refused to continue the study to the end. Subjects were divided into diabetics and non-diabetics groups. Spot urine protein/creatinine ratio, Urinary analysis, Alanine transaminase, Aspartate Transaminase, Creatinine, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Results
In the 9th month after therapy there was a significant relationship in mean change of Spot urine protein/creatinine ratio between diabetic and non-diabetic (p= 0.011). Spot urine protein/creatinine ratio in diabetic and non-diabetic group was 0.19±0.18 and 0.1±0.05, respectively which showed no significant relationship between the two groups at the end of study (P= 0.162).e, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Conclusion
The results of our study showed that consumption of deferasirox is safe since there was no significant relationship between Spot urine protein/creatinine ratio in diabetic and
non-diabetic group. Deferasirox consumption is not associated with increased proteinuria in diabetic patients compared to non-diabetic group having only a transient proteinuria.
Session topic: E-poster
Keyword(s): Patient, Thalassemia, Transfusion
Type: Publication Only
Background
Beta-Thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the Deferasirox is proteinuria.
Aims
This study aimed to investigate the safety of deferasirox on kidney function in diabetic and non-diabetic Beta-Thalassemia Major patients.
Methods
In this cross-sectional study, 70 patients who take deferasirox (Exjade-Novartis) 20-40mg/kg/day were studied. Exclusion criteria included patient with renal failure, proteinuria, hepatitis B, hepatitis C and the patients who refused to continue the study to the end. Subjects were divided into diabetics and non-diabetics groups. Spot urine protein/creatinine ratio, Urinary analysis, Alanine transaminase, Aspartate Transaminase, Creatinine, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Results
In the 9th month after therapy there was a significant relationship in mean change of Spot urine protein/creatinine ratio between diabetic and non-diabetic (p= 0.011). Spot urine protein/creatinine ratio in diabetic and non-diabetic group was 0.19±0.18 and 0.1±0.05, respectively which showed no significant relationship between the two groups at the end of study (P= 0.162).e, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Conclusion
The results of our study showed that consumption of deferasirox is safe since there was no significant relationship between Spot urine protein/creatinine ratio in diabetic and
non-diabetic group. Deferasirox consumption is not associated with increased proteinuria in diabetic patients compared to non-diabetic group having only a transient proteinuria.
Session topic: E-poster
Keyword(s): Patient, Thalassemia, Transfusion
Abstract: PB2220
Type: Publication Only
Background
Beta-Thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the Deferasirox is proteinuria.
Aims
This study aimed to investigate the safety of deferasirox on kidney function in diabetic and non-diabetic Beta-Thalassemia Major patients.
Methods
In this cross-sectional study, 70 patients who take deferasirox (Exjade-Novartis) 20-40mg/kg/day were studied. Exclusion criteria included patient with renal failure, proteinuria, hepatitis B, hepatitis C and the patients who refused to continue the study to the end. Subjects were divided into diabetics and non-diabetics groups. Spot urine protein/creatinine ratio, Urinary analysis, Alanine transaminase, Aspartate Transaminase, Creatinine, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Results
In the 9th month after therapy there was a significant relationship in mean change of Spot urine protein/creatinine ratio between diabetic and non-diabetic (p= 0.011). Spot urine protein/creatinine ratio in diabetic and non-diabetic group was 0.19±0.18 and 0.1±0.05, respectively which showed no significant relationship between the two groups at the end of study (P= 0.162).e, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Conclusion
The results of our study showed that consumption of deferasirox is safe since there was no significant relationship between Spot urine protein/creatinine ratio in diabetic and
non-diabetic group. Deferasirox consumption is not associated with increased proteinuria in diabetic patients compared to non-diabetic group having only a transient proteinuria.
Session topic: E-poster
Keyword(s): Patient, Thalassemia, Transfusion
Type: Publication Only
Background
Beta-Thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the Deferasirox is proteinuria.
Aims
This study aimed to investigate the safety of deferasirox on kidney function in diabetic and non-diabetic Beta-Thalassemia Major patients.
Methods
In this cross-sectional study, 70 patients who take deferasirox (Exjade-Novartis) 20-40mg/kg/day were studied. Exclusion criteria included patient with renal failure, proteinuria, hepatitis B, hepatitis C and the patients who refused to continue the study to the end. Subjects were divided into diabetics and non-diabetics groups. Spot urine protein/creatinine ratio, Urinary analysis, Alanine transaminase, Aspartate Transaminase, Creatinine, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Results
In the 9th month after therapy there was a significant relationship in mean change of Spot urine protein/creatinine ratio between diabetic and non-diabetic (p= 0.011). Spot urine protein/creatinine ratio in diabetic and non-diabetic group was 0.19±0.18 and 0.1±0.05, respectively which showed no significant relationship between the two groups at the end of study (P= 0.162).e, Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3 months. Patients were followed for a period of one year.
Conclusion
The results of our study showed that consumption of deferasirox is safe since there was no significant relationship between Spot urine protein/creatinine ratio in diabetic and
non-diabetic group. Deferasirox consumption is not associated with increased proteinuria in diabetic patients compared to non-diabetic group having only a transient proteinuria.
Session topic: E-poster
Keyword(s): Patient, Thalassemia, Transfusion
{{ help_message }}
{{filter}}